Wesbanco Bank Inc. Purchases 929 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Wesbanco Bank Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,991 shares of the biopharmaceutical company’s stock after acquiring an additional 929 shares during the period. Wesbanco Bank Inc.’s holdings in Gilead Sciences were worth $1,884,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the stock. Vanguard Group Inc boosted its holdings in Gilead Sciences by 1.1% during the third quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after buying an additional 1,071,619 shares during the last quarter. LeJeune Puetz Investment Counsel LLC boosted its holdings in Gilead Sciences by 12.4% during the fourth quarter. LeJeune Puetz Investment Counsel LLC now owns 23,305 shares of the biopharmaceutical company’s stock worth $1,458,000 after buying an additional 2,565 shares during the last quarter. DT Investment Partners LLC boosted its holdings in Gilead Sciences by 0.9% during the fourth quarter. DT Investment Partners LLC now owns 45,607 shares of the biopharmaceutical company’s stock worth $2,853,000 after buying an additional 386 shares during the last quarter. Benedict Financial Advisors Inc. boosted its holdings in Gilead Sciences by 1.1% during the fourth quarter. Benedict Financial Advisors Inc. now owns 26,040 shares of the biopharmaceutical company’s stock worth $1,629,000 after buying an additional 289 shares during the last quarter. Finally, First Personal Financial Services boosted its holdings in Gilead Sciences by 282.4% during the fourth quarter. First Personal Financial Services now owns 8,416 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 6,215 shares during the last quarter. 78.68% of the stock is owned by hedge funds and other institutional investors.

GILD has been the topic of a number of recent analyst reports. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. Credit Suisse Group began coverage on Gilead Sciences in a report on Monday, May 20th. They set a “neutral” rating and a $70.00 target price on the stock. JPMorgan Chase & Co. reiterated a “buy” rating and set a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday, May 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, May 6th. Finally, BMO Capital Markets began coverage on Gilead Sciences in a report on Thursday, March 14th. They set an “outperform” rating and a $78.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $79.54.

In related news, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the sale, the director now owns 34,669 shares of the company’s stock, valued at approximately $2,270,126.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. In the last three months, insiders sold 29,018 shares of company stock worth $1,914,428. 0.20% of the stock is owned by insiders.

Gilead Sciences stock traded up $0.48 during midday trading on Friday, reaching $67.56. The stock had a trading volume of 6,782,265 shares, compared to its average volume of 7,131,704. The company’s fifty day moving average is $66.14. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $79.61. The stock has a market capitalization of $85.01 billion, a PE ratio of 10.99, a P/E/G ratio of 3.11 and a beta of 1.10. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The business had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the firm earned $1.48 EPS. Gilead Sciences’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 6.6 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date of this dividend was Thursday, June 13th. Gilead Sciences’s dividend payout ratio is presently 40.98%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Stochastic Momentum Index (SMI)

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.